Concepedia

Author

Kamil Bojarczuk

Medical University of WarsawORCID

Also Known As

K Bojarczuk, K. Bojarczuk, KAMIL BOJARCZUK, Kamil Bojarczuk

45

Publications

1.3K

Citations

16

H-Index

42

Concepts

All Affiliations

Medical University of WarsawInstytut Hematologii i TransfuzjologiUniversitätsmedizin GöttingenHeidelberg UniversityDana-Farber Cancer Institute
KB

About

Kamil Bojarczuk is an author at Medical University of Warsaw specializing in medicine, cell biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

454

2

Engineering

1

1

30

3

Health Sciences

1

1

259

4

Biochemistry

1

1

259

5

Biomedical Engineering

1

1

30

Kamil Bojarczuk

×

16

Publications

1.1K

Citations

14

H-Index

YearCitations

Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer

Małgorzata Wachowska, Angelika Muchowicz, Małgorzata Firczuk,

Molecules

2011

259

Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion

Kirsty Wienand, Bjoern Chapuy, Chip Stewart,

Blood Advances

2019

155

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Kamil Bojarczuk, Binu K. Sasi, Stefania Gobessi,

Blood

2016

113

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Maher K. Gandhi, Thanh Hoang, Soi Cheng Law,

Blood

2020

112

TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer

Mengyu Tu, Lukas Klein, Elisa Espinet,

Nature Cancer

2021

110

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

Kamil Bojarczuk, Kirsty Wienand, Jeremy Ryan,

Blood

2018

93

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies

Małgorzata Bobrowicz, Michal Dwojak, Beata Pyrzyńska,

Blood

2017

50

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

Jacek Bil, Magdalena Winiarska, Dominika Nowis,

Blood

2010

45

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Anne C. Wilke, Carmen Doebele, Alena Zindel,

Blood

2021

42

CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas

Lin‐Feng Chen, Jing Ouyang, Kirsty Wienand,

Haematologica

2019

33

Page 1